Dryness, burning, sex that has started to hurt. Many women never mention them at all. Vaginal estrogen is one of the treatments the guidelines name for them, and it is a different thing from the HRT most people picture.
Vaginal estrogen
A low dose of estrogen used inside the vagina, for dryness, burning and pain with sex. What it is, how it differs from other HRT, and what to ask your doctor.
The words and the guidance
- English
- Vaginal estrogen
- Also searched as
- vaginal oestrogen, vaginal estradiol, vaginal oestradiol, local estrogen, local oestrogen, estrogen cream
- Urdu
- اسی جگہ لگانے والا ایسٹروجن
- Roman Urdu
- usi jagah lagane wala estrogen
What women actually say
- اسی جگہ لگانے والا علاج (usi jagah lagane wala ilaaj)Treatment applied right there. The words Roshara uses for local treatment, without naming the body part.
- NICE NG23 recommends offering vaginal estrogen to women with genitourinary symptoms of the menopause, including women already taking HRT, with regular review (recommendation 1.5.5). Genitourinary symptoms means vaginal dryness, pain with sex, irritation and discomfort when passing urine.
- NICE NG23 asks doctors to explain that serious side effects are very rare, that very little is absorbed into the bloodstream compared with HRT taken for the whole body, and that symptoms often come back when it is stopped (1.5.6).
- The Pakistan Menopause Society's 2026 recommendations say women using low-dose vaginal estrogen do not need an added progestogen (section 5.4).
- The NHS website says vaginal estrogen treats dryness and irritation but will not treat other menopause symptoms such as hot flushes, mood swings or problems sleeping.
What it is
Vaginal estrogen is a low dose of estrogen placed inside the vagina, where it acts on the tissues it is put on. Women's Health Concern calls this local HRT, and lists the forms it comes in: a cream, a gel, a tablet, a pessary or a ring.
It is meant for one group of symptoms, which the guidelines call genitourinary syndrome of menopause: vaginal dryness, soreness and irritation, pain during sex, and some bladder and urinary symptoms. The European Menopause and Andropause Society (EMAS) and The Menopause Society, in the US, say it may also help prevent repeat urine infections, and NICE's guideline on recurrent urine infections (NG112) asks doctors to consider it when simpler measures have not worked (1.2.1).
What it does not do matters just as much. The NHS website says it will not treat hot flushes, mood swings or problems sleeping. For those, a doctor would talk about HRT that works through the whole body.
Why it happens
As estrogen falls around the menopause, the tissues of the vagina and vulva can become thinner, drier and more easily sore.
NICE NG23 explains that vaginal estrogen is absorbed locally. Some does reach the bloodstream, but the amount is minimal compared with HRT for the whole body, and unlikely to have a significant effect elsewhere (1.5.6). The NHS website gives that as the reason you do not need a progestogen with it, even if you still have your womb.
What the guidelines say about treatment
NICE NG23 recommends offering vaginal estrogen to women with these symptoms, including women already on HRT, and reviewing it regularly (1.5.5). The doctor and the woman choose the form together (1.5.7), and EMAS considers all licensed vaginal estrogens equally effective. It can be used on its own or with non-hormonal moisturisers or lubricants (1.5.8). For women who cannot or would rather not use it, NICE suggests the moisturisers and lubricants on their own (1.5.9).
The British Menopause Society gives both as options too. It says moisturisers and lubricants can be used alongside vaginal estrogen, that they matter most for women who cannot use estrogen, and that moisturisers work best used regularly, not only around sex.
The Pakistan Menopause Society's recommendations prefer water-based and silicone-based products to glycerine-based ones (6.2), and list vaginal estrogen among the vaginal hormone options, with prasterone (5.5).
If neither suits, NICE lists ospemifene, a tablet, for women who find any treatment applied locally impractical (1.5.11).
The NHS website says it can take up to three months to work fully, and that early side effects such as headache usually settle in the first few months. NICE adds that symptoms often return when it is stopped, and it can be restarted (1.5.6).
After breast cancer
NICE NG23 treats this separately. For women who have had breast cancer, it recommends non-hormonal moisturisers or lubricants first (1.5.14). Vaginal estrogen can be considered if symptoms carry on despite those (1.5.15), and for women taking aromatase inhibitors, the doctor should work with a breast cancer specialist (1.5.16). NICE says it is not known whether vaginal estrogen affects the risk of breast cancer coming back. For estrogen receptor-negative cancer it says any risk is unlikely; for estrogen receptor-positive cancer, unknown, though medicines such as tamoxifen would reduce any such effect (1.5.17 to 1.5.19).
Available in Pakistan?
Yes, online. The Pakistan Menopause Society's 2026 list of menopause hormone products available in Pakistan (Table 10) includes a vaginal conjugated estrogen product, marked as sold online.
When to see a doctor
If dryness or pain has gone on for weeks, it is worth an appointment.
See a doctor promptly about any bleeding after sex or after your periods have stopped. The PMS recommendations list both among the red flags that need checking (2.3).
The PMS recommendations note that many Pakistani women may not mention sexual or urinary symptoms unless asked respectfully and in private (2.2). You can write the symptom down and hand it over, or ask whether a female doctor is available.
Questions to ask your doctor
- Could my dryness, burning or pain with sex be from the menopause, or is there anything else it could be?
- Would vaginal estrogen suit me, and in which form: a cream, a gel, a tablet, a pessary or a ring?
- Can I use a moisturiser or lubricant as well, or instead?
- I have had breast cancer. What are my options, and should my cancer team be involved?
Faith and family
An applicator, a pessary, a cream: for some women that is simply a medicine. For others it raises questions they have never had to ask before, about modesty, about touching or inserting anything, about wudu and ghusl, or about using it on a fasting day. Women ask these questions, and they rarely get a clear answer.
Questions about prayer, purity and the fast belong with a qualified scholar. Questions about when to use the treatment, or whether a different form would make things easier, belong with whoever prescribes it.
Track it
- Roshara's symptom score rates 27 symptoms in a few minutes, with no account. The total is something to take to your appointment. Take the symptom score
- Where am I? names the stage you might be in. Six questions. Take Where am I?
- Log it day by day in the tracker, with what came just before. It needs a free account. Open the tracker
Common questions
- Is vaginal estrogen the same as HRT?
- It is a form of HRT, but a local one. The NHS website says little of the medicine gets into the rest of the body, so it treats dryness and irritation but not hot flushes or mood. (Source: NHS website, About vaginal oestrogen (reviewed 27 January 2023, review was due 27 January 2026))
- Can I use it after breast cancer?
- NICE NG23 says it can be considered if symptoms continue despite non-hormonal moisturisers or lubricants (1.5.15). The section below sets out the detail. (Source: NICE NG23, Menopause: identification and management (last updated 15 April 2026))
- How long can I use it?
- The Menopause Society says low-dose vaginal estrogen can be considered at any age and for as long as it is needed. EMAS says women should not be denied long-term use if they feel it helps. (Source: The Menopause Society (then The North American Menopause Society), The 2022 hormone therapy position statement, Menopause 2022;29(7):767-794)
- The leaflet in the box warns about breast cancer and stroke. Does that apply to me?
- The Menopause Society says those warnings list the risks of HRT for the whole body, and that with so little absorbed at these low doses, they are highly unlikely. If you have had breast cancer, see the section below. (Source: The Menopause Society (then The North American Menopause Society), The 2020 genitourinary syndrome of menopause position statement, Menopause 2020;27(9):976-992)
- Does it raise the risk of clots? I take a blood thinner.
- EMAS says vaginal estrogen is not linked with a higher risk of clots, and can be prescribed for women on long-term blood thinners. (Source: European Menopause and Andropause Society, Menopause Essentials 2026: Risk of venous thromboembolism (July 2026))
Sources
- NICE NG23, Menopause: identification and management (last updated 15 April 2026)Section: 1.5.5 to 1.5.19, Genitourinary symptoms associated with menopause · Opened 1 October 2026
- NHS website, About vaginal oestrogen (reviewed 27 January 2023, review was due 27 January 2026)Section: About vaginal oestrogen; Key facts · Opened 1 October 2026
- Women's Health Concern, Vaginal dryness (factsheet, reviewed October 2023, next review October 2026)Section: Treatment; Helpful vocabulary · Opened 1 October 2026
- British Menopause Society, Consensus statement: Genitourinary syndrome of menopause (GSM) (reviewed November 2025)Section: Non-hormonal lubricants and moisturisers; Vaginal estrogen · Opened 10 October 2026
- Pakistan Menopause Society, Good Clinical Practice Recommendations for Menopause Care in Pakistan (JSOGP 16(2), 28 April 2026)Section: 2.2; 2.3; 5.4; 5.5; 6.2; Table 10 · Opened 1 October 2026
- NICE NG112, Urinary tract infection (recurrent): antimicrobial prescribingSection: 1.2.1, Treatments for preventing recurrent UTI: oestrogen · Opened 15 October 2026
- The Menopause Society (then The North American Menopause Society), The 2022 hormone therapy position statement, Menopause 2022;29(7):767-794Section: Menopause symptoms: urinary tract symptoms; Duration of use (key points) · Opened 15 October 2026
- The Menopause Society (then The North American Menopause Society), The 2020 genitourinary syndrome of menopause position statement, Menopause 2020;27(9):976-992Section: Conclusions and recommendations · Opened 15 October 2026
- European Menopause and Andropause Society, Menopause Essentials 2026: Topical estrogens (July 2026)Section: Practical issues; Safety · Opened 15 October 2026
- European Menopause and Andropause Society, Menopause Essentials 2026: Vulvovaginal atrophy (July 2026)Section: Other options · Opened 15 October 2026
- European Menopause and Andropause Society, Menopause Essentials 2026: Risk of venous thromboembolism (July 2026)Section: Menopausal hormone therapy (MHT) for women with VTE · Opened 15 October 2026